Evidence map›Paper›PMID 41047440›Full record

ReviewThe protein journal2025

Unlocking the Therapeutic Potential of Cyclic Peptide-Based Nanocarriers for Enhanced Colon Cancer Treatment.

Vedhapriya Souresh, M Srikayalsamyukktha, M Harini, Yudhesh Saravanan, Rupachandra Saravanakumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in The protein journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vedhapriya SoureshDepartment of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India.
M SrikayalsamyukkthaDepartment of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India.
M HariniDepartment of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India.
Yudhesh SaravananDepartment of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India.
Rupachandra SaravanakumarDepartment of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603 203, India. rupachas@srmist.edu.in.ORCID http://orcid.org/0000-0001-5140-5989

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclic peptides have emerged as therapeutic agents for colon cancer due to their structural stability, enhanced bioavailability, and high target specificity. Natural cyclic peptides derived from plant, marine, and microbial sources exhibit potent anticancer properties. Advancements in nanotechnology have facilitated using cyclic peptide-based nanocarriers to improve drug delivery, enhance tumor penetration, and minimize adverse effects. Nanocarriers including liposomes, niosomes, nanosponges, and nanopolymers provide a revolutionary approach by facilitating localized distribution, enhanced stability, and controlled release of cyclic peptides. This strategy improves pharmacokinetics and lowers systemic toxicity to overcome the limitations of conventional treatments. Recent developments in cyclic peptide-based nanotechnology demonstrate the synergy between cyclic peptides and nanocarriers in overcoming drug resistance in colon cancer. This review provides a comprehensive overview of the sources, mechanisms of action, and therapeutic applications of cyclic peptides in colon cancer treatment. It further explores the role of cyclic peptide-functionalized nanocarriers in overcoming drug resistance and improving drug delivery.

Indexed as

Antineoplastic AgentsColonic NeoplasmsDrug CarriersNanoparticlesPeptides, CyclicAnimalsDrug Delivery SystemsHumansAntineoplastic AgentsDrug CarriersPeptides, CyclicColon cancerCyclic peptidesDrug deliveryNanocarrier

Identifiers

PMID41047440

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.